-
-
-
-
E610169-25mgeravacycline.
-
-
-
-
E414001-100mgInformationErdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, panfibroblast growth factor receptor (FGFR)inhibitor with potential antineoplastic activity. Erdafitinib also binds toRET (c-RET),CSF-1R,PDGFR-α/PDGFR-β,FLT4,Kit
-
E414001-10mgInformationErdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, panfibroblast growth factor receptor (FGFR)inhibitor with potential antineoplastic activity. Erdafitinib also binds toRET (c-RET),CSF-1R,PDGFR-α/PDGFR-β,FLT4,Kit
-
E414001-2mgInformationErdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, panfibroblast growth factor receptor (FGFR)inhibitor with potential antineoplastic activity. Erdafitinib also binds toRET (c-RET),CSF-1R,PDGFR-α/PDGFR-β,FLT4,Kit
-
E414001-50mgInformationErdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, panfibroblast growth factor receptor (FGFR)inhibitor with potential antineoplastic activity. Erdafitinib also binds toRET (c-RET),CSF-1R,PDGFR-α/PDGFR-β,FLT4,Kit
-
E414001-5mgInformationErdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, panfibroblast growth factor receptor (FGFR)inhibitor with potential antineoplastic activity. Erdafitinib also binds toRET (c-RET),CSF-1R,PDGFR-α/PDGFR-β,FLT4,Kit